Proactively mitigating contamination risk across the end-to-end cell therapy manufacturing workflow

Wednesday 09:00 PDT / 12:00 EDT / 16:00 GMT / 17:00 CET

Sponsor

Proactively mitigating contamination risk across the end-to-end cell therapy manufacturing workflow

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

Short product shelf life, scalability challenges, increasing levels of regulatory scrutiny, and the high cost of contamination events together create a ‘perfect storm’ for cell therapy manufacturers.

This webinar will provide practical tools and insights to address all four elements, helping to minimize both in-process and lot release testing timelines and contamination risk whilst enhancing scalability and alignment with regulators’ current expectations.

The presentation will also share concrete data and real-world examples demonstrating the sensitivity of qPCR-based mycoplasma detection down to 10 genome copies/mL in T-cell samples, comparisons between traditional 28-day mycoplasma and 14-day sterility tests versus rapid qPCR alternatives that deliver results in hours, and examples of microbial identification for potential root cause analysis supporting both small-scale autologous and large-scale allogeneic processes.

Attend this webinar to gain:

A risk-based framework spanning upstream processing and QC analytics, which can be applied to contamination control in autologous and allogeneic cell processing workflows
Improved practical understanding of rapid mycoplasma and sterility testing approaches that enable same-day decision-making
Actionable considerations for selecting analytical assays that balance performance, operational fit, and regulatory expectations

Suzy Brown

Senior Field Applications Specialist at Thermo Fisher Scientific

Suzy Brown is a Senior Field Application Scientist for Pharma Analytics- Bioproduction, supporting customers in the UK and Ireland. She has been with Thermo Fisher Scientific for 8 years, where she provides training and implementation of the Pharma Analytics portfolio. During this time, she has taken on the role of MycoSEQ subject matter expert for the EMEA region.

Suzy gained a Cell Biology Degree, and later a Developmental Biology PhD at the University of Manchester (UK), where she applied molecular, proteomic and Next Generation Sequencing approaches to identify genes required for pattern formation in model organism Dictyostelium discoideum development. Following university, Suzy moved into the Biopharmaceutical Industry and worked as an Analytical Development Scientist for 3 years at Allergan Biologics, within a Molecular Biology team, and has experience in qPCR, Sanger Sequencing, and impurity testing.

You have registered for this webinar